Why Natera’s Stock Is Sliding Despite Bullish Outlook

Natera ( (NTRA) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.

Natera’s share price came under pressure as investors focused on the company’s wider GAAP losses and a recent pickup in insider stock sales, which raised concerns despite otherwise positive business trends. Analysts responding to the news maintained a generally upbeat long‑term view, highlighting Natera’s strong position in minimal residual disease testing through its Signatera platform, growing reimbursement and adoption, improving margins, and solid revenue growth prospects. They also noted a new collaboration that will use Signatera in a pivotal colorectal cancer trial and expressed confidence in robust fourth‑quarter results and a favorable 2026 outlook, leading them to adjust their price targets accordingly rather than abandon their bullish stance.

More about Natera

YTD Price Performance: 8.58%

Average Trading Volume: 1,332,346

Technical Sentiment Signal: Buy

Current Market Cap: $32.84B

For further insights into NTRA stock on TipRanks’ Stock Analysis page.

See more of today’s top stock gainers and losers.